China SXT Pharmaceuticals-ASXTC
13F holders, Q2 2026 (June 30)3holders −1
0new positions
1sold out
$0.38avg. 13F price*
At the end of Q2 2026, 3 institutions reported holding China SXT Pharmaceuticals-A (SXTC) in their 13F filings, down 1 from Q1 2026. 0 opened new positions and 1 sold out. The largest holders were Caitong International Asset Management Co., Ltd ($4), UBS Group AG ($2) and Royal Bank of Canada ($0).
- Company
- China SXT Pharmaceuticals-A
- CUSIP
- G2161P165
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $131K |
All 13F filers, Q1 2026 → Q2 2026: 1 shares bought and 78,170 shares sold, net −78,169 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Caitong International Asset Management Co., Ltd | 0.00% | Add +100.0% | 2 | $4 |
| UBS Group AG | 0.00% | No change | 1 | $2 |
| Royal Bank of Canada | 0.00% | No change | 13 | $0 |
"% of holder's portfolio" is SXTC's weight in each manager's 13F, not the share of China SXT Pharmaceuticals-A the manager owns.